

# Proteomics International Laboratories

10:00 04 Apr 2017

## Proteomics International Laboratories targets first sales in 2017

Proteomics International Laboratories (ASX:PIQ) is targeting first commercial sales at the calendar year end for PromarkerD, a world leading diagnostic test for diabetic kidney disease.

Sales will be in the Dominican Republic in Latin America as a result of Proteomics' first licensing deal.

Proteomics sees its market as worldwide and it has patents are now granted in the U.S., Australia, Russia, Singapore and China, covering a potential market size of 153 million adult diabetics.

The company is in discussion with pathology laboratories and diagnostic companies in Australia, Japan and the U.S. for the commercial use of PromarkerD as an in vitro diagnostic device (IVD).

A recent Frost & Sullivan independent report has identified PromarkerD as the world leader with high adoption potential across the Asia Pacific.

### PromarkerD

PromarkerD is a predictive diagnostic test for diabetic kidney disease and is patented in both Singapore and China.

Results have shown PromarkerD can correctly predict 95% of the previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.

There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggests Proteomics is one of only two companies worldwide developing such a test.

Proteomics is rated at the forefront of using proteomics technology for diabetes diagnostics worldwide, and has already been granted patents for PromarkerD in China, Singapore, Russia, Australia and the U.S.

### Next steps

Data from Proteomics' follow-up validation study on the diabetic kidney disease predictive test has been collected and the interpretation of the results is now pending.

Results from this independent study will be presented via forums such as the American Diabetes Association, and released once the peer-review process has been completed appropriately.

**Price:** A\$0.2

**Market Cap:** A\$10.62M

### 1 Year Share Price Graph



### Share Information

**Code:** PIQ

**Listing:** ASX

<b>52 week</b>	<b>High</b>	<b>Low</b>
	0.3p	0.16p

**Sector:** Pharma & Biotech

**Website:**  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

### Company Synopsis:

*Proteomics International Laboratories Ltd (ASX:PIQ) is listed on the Australian Securities Exchange.*

### Author:

**Proactive Investors Australia**

**+61 (0)2 9280 0700**

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

For these clinical studies Proteomics continues to work closely with the University of Western Australia Medical School and Fremantle Diabetes Study.

### The global opportunity

Worldwide this number is forecast to rise to 642 million people by 2040, and 214 million people are predicted to get chronic kidney disease as a result.

Kidney disease is one of the major complications of diabetes and affects circa one-third of all adult diabetics.

Keeping people alive on dialysis costs more than \$100,000 per person per year and globally the diabetes epidemic cost health systems \$673 billion dollars in 2015.

PromarkerD provides countries and the world with a potential solution to this costly disease.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.